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Abstract
Insulin-degrading enzyme (IDE) is a thiol sensitive peptidase that degrades insulin and amyloid b, and has been linked to
type 2 diabetes mellitus and Alzheimer’s disease. We examined the thiol sensitivity of IDE using S-nitrosoglutathione,
reduced glutathione, and oxidized glutathione to distinguish the effects of nitric oxide from that of the redox state. The in
vitro activity of IDE was studied using either partially purified cytosolic enzyme from male Sprague-Dawley rats, or purified
rat recombinant enzyme. We confirm that nitric oxide inhibits the degrading activity of IDE, and that it affects proteasome
activity through this interaction with IDE, but does not affect the proteasome directly. Oxidized glutathione inhibits IDE
through glutathionylation, which was reversible by dithiothreitol but not by ascorbic acid. Reduced glutathione had no
effect on IDE, but reacted with partially degraded insulin to disrupt its disulfide bonds and accelerate its breakdown to
trichloroacetic acid soluble fragments. Our results demonstrate the sensitivity of insulin degradation by IDE to the redox
environment and suggest another mechanism by which the cell’s oxidation state may contribute to the development of,
and the link between, type 2 diabetes and Alzheimer’s disease.
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Introduction
Insulin-degrading enzyme (IDE, EC 3.4.24.56) hydrolyzes a
number of small (,12,000 MW) peptides, notably insulin and
Alzheimer’s amyloid b peptide. As such, it has been implicated in
the etiology of both type 2 diabetes (T2DM) and Alzheimer’s
disease (AD). The Goto-Kakizaki rat, an animal model of T2DM,
contains mutations in the IDE gene and exhibits elevated blood
glucose and insulin levels [1]. IDE knockout mice are both
glucose-intolerant and hyperinsulinemic, supporting the concept
that IDE is important in the maintenance of normal blood glucose
and insulin levels [2]. Human genetic studies have linked
polymorphisms in the IDE gene to an increased risk for insulin
resistance and T2DM [3,4,5]. IDE hypofunction has been shown
to contribute to the accumulation of Ab plaques in animal models
of AD [2]. Human genetic studies have also linked IDE to AD
[6,7,8]. Thus, factors that affect the activity of IDE, such as post-
translational modification, could have significant impact on the
progression of these diseases.
IDE is a ubiquitously expressed zinc metalopeptidase that is
inhibited by thiol reactive agents [9]. The cysteines most likely
responsible for this thiol sensitivity have been identified [10]. We
and others have shown that nitric oxide (NO) is capable of reacting
with IDE and inhibiting activity [11,12]. Both T2DM and AD
have been associated with a chronic inflammatory state, which
may result in locally increased iNOS expression and NO release
[13,14,15,16,17]. In further study of this phenomenon, we have
used the NO donor S-nitrosoglutathione (GSNO), which may be a
physiological sink for NO in cells [18,19]. Our results further
characterize our previous report, but also demonstrate a role for
glutathione in the control of insulin degradation by interaction
with both IDE and partially degraded insulin itself. This is
significant because of the change in cellular redox state found in
both diabetes and AD.
In this study, we examined the effects of S-nitrosoglutathione
(GSNO), reduced glutathione (GSH), and oxidized glutathione
(GSSG) on IDE function. We show that GSNO inhibits IDE-
mediated degradation of two IDE substrates, insulin and Ab, and
that IDE-mediated regulation of the proteasome is inhibited. We
also found that GSSG inhibits IDE while GSH increased the
breakdown of partially-degraded insulin. Taken together, these
findings demonstrate potential pathways by which imbalances in
the oxidative state may contribute to the pathology of T2DM and
AD, and represent potential therapeutic targets for the treatment
of these diseases.
Materials and Methods
Chemicals
S-nitrosoglutathione (GSNO), GSSG, GSH, and the fluoro-
genic proteasome substrate succinyl-leu-leu-val-tyr-7-amido-4-
methyl coumarin (LLVY) were purchased from Sigma (St.
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compose to release NO from the compound, which can be
followed by measuring absorbance at 340 nm [20,21]. Decom-
position was accomplished by incubating GSNO at room
temperature in the dark for 72 hours.
125I-human recombinant
insulin and
125I-b-amyloid were purchased from GE Healthcare
Life Sciences (Piscataway) and Phoenix Pharmaceuticals (Bur-
lingame), respectively. Polyclonal anti-IDE antibody and the
monoclonal anti-glutathione antibody were purchased from
Millipore. All other chemicals were of at least reagent grade.
S-methyl methanethiosulfonate (MMT) was from Aldrich
(St. Louis). N-[6-(Biotinamido)hexyl]2392(29-pyridyldithio) pro-
pionamide (biotin-HPDP) was from Thermo Scientific (Rock-
ford). IRDye 800 CWH Streptavidin was from LiCor Biosciences
(Lincoln).
Enzyme Preparation
Male Sprague-Dawley rats were maintained and used in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals, under a protocol (ID#
00319) approved by the Subcommittee of Animal Studies and the
Research and Development Committee of the Omaha Veterans
Affairs Medical Center. Insulin-degrading enzyme/proteasome
was prepared from rat muscle or liver by ultracentrifugation and
ammonium sulfate precipitation, similar to that described
previously [22]. This preparation was used, rather than a more
purified form of IDE, so that we could study the interaction with
the proteasome. IDE is the only insulin-degrading activity in this
preparation (data not shown). Purified proteasome was obtained
from Sigma (St. Louis, MO). Purified IDE was purchased from
EMD Chemicals, Inc (Gibbstown, NJ).
Insulin Degradation
The degradation of
125I-insulin and
125I-b-amyloid was
measured by the trichloroacetic acid (TCA) solubility method.
GSSG, GSH, and GSNO, and oxidized GSNO (GSNO(ox)) were
solubilized in the assay diluent (100 mM Tris-Cl). An aliquot of rat
enzyme was pretreated with GSNO and GSNO(ox) for 1 hour
prior to the insulin degradation assay. The enzyme preparation
was incubated with increasing concentrations of GSH, GSSG,
GSNO, and GSNO(ox) (with and without ascorbate [10
23 M])
and
125I-insulin or
125I-b-amyloid for 15 minutes at 37uC. The
reaction was stopped by addition of 0.5% (final) BSA and 10%
(final) TCA. Samples were centrifuged, and the supernatant and
pellet counted using a gamma counter, with data expressed as
percent degradation relative to untreated enzyme. Substrate
incubated without enzyme was subtracted as background
solubility. For the enzyme inactivation experiments, prior to the
addition of BSA and TCA, the samples were heated for 8 minutes
at 90uC, cooled to approximately 40uC, 10
22 M GSH was added,
and the samples were incubated an additional 15 minutes at 37uC
before the reaction was stopped.
Nitrosylation of IDE
Nitrosylation of IDE was assessed by a modification of the
biotin switch method [23,24]. The samples were acetone
precipitated between each step. Purified IDE was incubated
without and with 10
24 M GSNO and GSNO(ox) for 2 hours at
37uC in 100 mM Tris, pH 7.5. The samples were resuspended in
HENS buffer (0.25 M HEPES, 1 mM EDTA, 0.1 M neocu-
prione, 1% SDS) with 20 mM MMT and incubated for 30
minutes at 50uC to block free sulfhydryls. The precipitated
samples were resuspended in HENS buffer without or with
2.6 mM biotin-HPDP and ascorbate, and incubated for 1 hour at
room temperature. The samples were run on non-reducing gels,
and transferred to PVDF membrane and probed with IRdye
streptavidin. Blots were visualized on an OdysseyH infrared
imaging system.
Figure 1. GSNO and GSNO(ox) inhibit IDE. The effect of 10
24 M
GSNO or GSNO(ox) on
125I-Insulin degradation by partially purified liver
IDE is shown in the absence (open bars) or presence (grey bars) of
ascorbate [10
23 M]. Inhibition by GSNO (NO donor) is prevented by
ascorbate, while GSNO(ox) inhibition is not. All graphs represent the
mean 6 SEM of at least three independent experiments. *P,0.01com-
pared to no addition. #P,0.01 compared to GSNO without ascorbate.
doi:10.1371/journal.pone.0018138.g001
Figure 2. Nitrosylation of IDE by GSNO. The nitrosylation of purified recombinant IDE by GSNO, but not GSNO(ox) is demonstrated using the
biotin switch method. IDE was either not treated (lanes 2 and 6), treated with 10
24 M GSNO(ox) (lanes 3 and 7) or 10
24 M GSNO (lanes 4 and 8). Lanes
2 through 4 show controls without the biotin reagent. Lanes 6 through 8 show enzyme subjected to biotin labeling. Lanes 1 and 5 are molecular
weight markers with indicated MW. IDE at approximately 110 K MW is indicated.
doi:10.1371/journal.pone.0018138.g002
Redox Control of IDE
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The degradation of the fluorogenic peptide substrate, LLVY,
was used as a measure of the chymotrypsin-like activity of the
proteasome [25]. Aliquots of rat muscle enzyme preparation or
purified proteasome were incubated with increasing concentra-
tions of GSH, GSSG, GSNO and GSNO(ox) with and without
ascorbate [1x10
23 M] in a 96-well black plate at 37uC for 1 hour.
LLVY was added (13 mM final concentration), and florescence
measurements (excitation/emission: 355/460 nm) were taken at
30, 60, 90, and 120 minutes post-addition using a Perkin-Elmer
Victor
3 1420 multilabel counter. Data are expressed as the rate of
change in fluorescence units and normalized to the activity of
untreated enzyme.
HPLC Analysis of Insulin Degradation Products
Rat liver IDE was preincubated with GSNO or GSNO(ox) for
1 hour at 37uC in 100 mM Tris-Cl buffer. For experiments with
GSH or GSSG, the enzyme was not pretreated. The enzyme
samples were then incubated with approximately 5610
5 cpm
125I-insulin for 5 minutes at 37uC, and then applied directly to a
reversed-phase HPLC column, similar to that previously described
[26]. Fractions of the eluate were collected and analyzed using a
gamma-counter to determine the elution profile of radioactivity.
Glutathionylation of insulin-degrading enzyme
Partially purified rat enzyme was incubated with GSH, GSSG,
GSNO, or GSNO(ox) for 1 hour at 37uC. The samples were then
mixed with loading dye without b-mercaptoethanol and resolved
on polyacrylamide gels with SDS. Samples were then transferred
to PVDF membranes and probed for IDE and glutathione
modification.
Data Analysis
Results are expressed as mean 6 SEM. Data were analyzed
using the Prism GraphPad statistical software (Version 5, La Jolla,
CA). Significance was determined by one-way ANOVA with
Dunnett’s multiple comparison test.
Results
The effects of the NO donor compound, GSNO and the
control compound GSNO(ox) on the insulin-degrading activity of
IDE are shown in Figure 1. Both compounds inhibit insulin
degradation. The addition of ascorbate (10
23 M) partially
reverses the inhibitory effect of GSNO, but had no effect on
GSNO(ox). Ascorbate alone had no effect on insulin degradation.
Since ascorbate is known to reverse potential nitrosylative effects,
this suggests GSNO is working via NO donation. The nitrosyla-
tion of IDE by GSNO, but not GSNO(ox) is confirmed in
Figure 2, using the biotin switch method. Neither GSNO nor
GSNO(ox) had any qualitative effect on the insulin fragments
generated as assessed by HPLC (data not shown), suggesting that
nitrosylation decreases the rate of hydrolysis, but not the
specificity of IDE.
Our lab has previously shown that substrates and inhibitors of
IDE will decrease the chymotrypsin- and trypsin-like activities of
Figure 3. Proteasome chymotrypsin-like activity with GSNO and GSNO(ox) treatment. Partially-purified rat IDE enzyme with proteasome
was treated with increasing concentrations of NO donor and assessed for chymotrypsin-like activity using a fluorogenic proteasome substrate.
(A) Proteasome activity with GSNO (#), GSNO+Ascorbate [10
23 M] (N). (B) Proteasome activity with GSNO(ox) (%), GSNO(ox)+Ascorbate [10–3 M]
(&). Inhibition by GSNO (NO donor) is prevented by ascorbate, while GSNO(ox) inhibition is not. Mean 6 SEM of at least three independent
experiments; **P,0.01 compared to no addition.
doi:10.1371/journal.pone.0018138.g003
Figure 4. Effect of GSNO or GSNO(ox) on purified proteasome.
Purified proteasome (no IDE) was treated with increasing concentra-
tions of NO donor and assessed for chymotrypsin-like activity using a
fluorogenic proteasome substrate; GSNO (#), GSNO(ox) (%). Purified
proteasome is not susceptible to inhibition by NO. Mean 6 SEM of
three experiments; a is P,0.05 compared to no addition; b is P,0.05
GSNO(ox) compared to GSNO at 10
25 M; c is P=0.058 GSNO(ox)
compared to GSNO at 10
24 M.
doi:10.1371/journal.pone.0018138.g004
Redox Control of IDE
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Thus, we tested our in vitro rat enzyme preparation containing
isolated IDE and proteasome complex to see whether or not
GSNO or GSNO(ox) would have an effect on proteasome
activity. We treated the IDE-proteasome complex with GSNO
(Figure 3A) and GSNO(ox) (Figure 3B) in the presence and
absence of ascorbate and examined the chymotrypsin-like
activity. GSNO inhibited the proteasome activity by 50%,
whereas in the presence of ascorbate the effect was greatly
diminished. This indicates that the inhibitory effect observed with
GSNO treatment of the proteasome is reversible, which was also
seen in the insulin degradation assays. In contrast, GSNO(ox)
Figure 5. Glutathionylation of IDE by GSNO(ox). Post-translational modification of IDE by glutathionylation was measured by Western blotting
with an anti-glutathione antibody (right panel). Anti-IDE blot of the same gel is shown in the left panel. Partially-purified IDE was left untreated (lane
1) or treated with GSNO [10
26,1 0
25,o r1 0
24 M, lanes 2 to 4 respectively] or GSNO(ox) [10
26,1 0
25,o r1 0
24 M, lanes 6–8, respectively]. Molecular
weight markers, with their sizes indicated, are in lane 5. Lane 8 (right panel) shows increased glutathione staining with GSNO(ox), while GSNO had no
effect. Blot is representative of 4 similar experiments.
doi:10.1371/journal.pone.0018138.g005
Figure 6. Glutathionylation of purified IDE by GSSG. Post-translational modification of IDE by glutathionylation was measured by Western
blotting with an anti-glutathione antibody (right panel). Anti-IDE blot is shown on the left. Partially-purified IDE was left untreated (lane 1) or treated
with GSH [10
24,1 0
23,o r1 0
22 M, lanes 2 to 4 respectively] or GSSG [10
24,1 0
23,o r1 0
22 M, lanes 7 to 9, respectively]. Molecular weight markers, with
their sizes indicated, are in lane 5. Lane 6 is a blank. GSSG dose-dependently increased glutathionylation of IDE, while GSH had no effect. Blot is
representative of 4 similar experiments.
doi:10.1371/journal.pone.0018138.g006
Figure 7. Effect of GSH and GSSG on insulin degradation.
125I-Insulin degradation by IDE is shown after treatment with GSH and GSSG in the
presence and absence of ascorbate [10
23 M]. (A) Insulin degradation curve fit with increasing concentrations of GSH (#) and GSSG (%). (B) Insulin
degradation curve fit with GSH+Ascorbate [10
23 M] (N) and GSSG+Ascorbate [10
23 M] (&). GSSG inhibits IDE, while GSH appears to increase activity.
Mean 6 SEM of at least 3 independent experiments; *P,0.05, **P,0.01 compared to no addition.
doi:10.1371/journal.pone.0018138.g007
Redox Control of IDE
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However, the effect on the proteasome activity may have been
due to direct action on the proteasome and not through IDE.
Thus, we used a purified 20 S proteasome preparation to
examine the effects of GSNO and GSNO(ox) on the chymotryp-
sin-like activity. GSNO had no effect on the proteasome, while
GSNO(ox) did directly inhibit (Figure 4). Together with Figure 3,
these results indicate NO does not affect the proteasome directly,
but works though its reversible interaction with IDE. However,
GSNO(ox) works on both enzymes and is not affected by
ascorbate.
Low-molecular weight nitrosothiols, such as GSNO, have been
shown to glutathionylate protein cysteine residues, probably
through reactive intermediates generated in its breakdown [29].
Thus, glutathionylation of IDE with GSNO and GSNO(ox)
treatment was explored using an anti-glutathione antibody
(Figure 5). The partially purified IDE preparation appears to
show a low level of endogenous glutathionylation, which increases
significantly with GSNO(ox) at 10
24 M. GSNO has been reported
to decompose to the reduced and oxidized forms of glutathione, as
well as oxidized glutathione derivatives [30,31], suggesting that
GSH or GSSG may modify IDE.
However, there is conflicting evidence as to which component
of GSNO decomposition is most effective at glutathionylation
[31,32,33]. Therefore we examined the ability of both GSH and
GSSG to glutathionylate IDE (Figure 6). The recombinant
purified form of IDE showed no glutathionylation. GSH had no
effect, whereas GSSG showed a dose-dependent increase in
glutathionylation of IDE. Thus, inhibition by GSNO(ox) likely
works by modification of IDE via GSSG. These findings prompted
us to examine the effect of two potential GSNO decomposition
products, GSH and GSSG, on IDE-mediated degradation of
insulin and Ab.
The effect of GSH and GSSG on IDE-mediated degradation
of insulin is shown in Figure 7. Partially purified rat IDE activity
was significantly inhibited by at least 40% at 10
23 M of GSSG
and by more than 90% at 10
22 M. Conversely, GSH appeared
to have significantly increased insulin degradation, more than
doubling TCA solubility at 10
22 M. A similar increase in
solubility is seen with the reducing agent dithiothreitol (DTT,
data not shown). Figure 7B shows the effect of GSH and GSSG
on IDE degradation of insulin in the presence of 10
23 M
ascorbate. Ascorbate did not alter either of the curves, suggesting
the effects of GSH and GSSG, unlike nitrosylation, are not
reversible with the relatively low reducing power of ascorbate.
Similar results were obtained with a purified form of IDE (data
not shown).
If GSSG inhibits IDE by glutathiolation, it should be reversible
with a strong enough reducing agent. We therefore incubated
IDE without and with 1 mM GSSG, dialyzed the preparations
against Tris buffer without and with 1 mM DTT, and assayed for
insulin degradation. The final assay did not contain sufficient
DTT to reduce the disulfide bonds of insulin (data not shown).
The data in Figure 8 show that inhibition by GSSG is reversible
with DTT. In fact, DTT treatment increased insulin degrading
activity in both the GSSG treated and control preparations. This
latent activity suggests the original preparation had some IDE
Figure 8. Inhibition of IDE by GSSG is reversible with DTT. IDE
was incubated without or with GSSG (10
24 M) and then dialyzed in the
absence (open bars) or presence (shaded bars) of DTT (10
22 M) before
assay of insulin degrading activity. GSSG inhibits IDE, while DTT reverses
the effect and reveals latent degrading activity. Mean 6 SEM of three
replicates. The graph is representative of 4 independent experiments
with varying levels of insulin degradation (TCA solubility).
doi:10.1371/journal.pone.0018138.g008
Figure 9. Direct effect of GSH on the partially-degraded
125I-insulin and
125I-amyloid-b. Substrates were incubated with IDE in the
presence of GSH or GSSG [10
22 M]; left side of each graph. Alternatively, IDE was incubated with substrate and GSH or GSSG, then IDE was heat-
inactivated. An additional 10
22 M GSH was added after enzyme inactivation and incubated for another 15 min before TCA precipitation (right side of
each graph). Gray bars are Untreated Enzyme; white bars are Enzyme + GSH; black bars are Enzyme + GSSG. (A) Insulin degradation. (B) Amyloid b
degradation. Background TCA solubility in the absence of enzyme was subtracted. Treatment with GSH after heat inactivation of the enzyme
increases TCA solubility of insulin products by breaking disulfides. Amyloid-b, not having any disulfide bonds, is unaffected either before or after
enzyme inactivation. Mean 6 SEM of three independent experiments. *P,0.05, **P,0.01 compared to control.
doi:10.1371/journal.pone.0018138.g009
Redox Control of IDE
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consistent with our finding of a low level of glutathionation
(Figure 5).
Insulin has three disulfide bonds, two of which join the A-Chain
and B-Chain of insulin together, and sufficiently high concentra-
tions of GSH, such as those used in the previous assays, can reduce
disulfide bonds. We next examined whether the observed increase
in insulin degradation by GSH was due to an increase in enzyme
activity or an increase in substrate solubility via a direct effect of
GSH on partially-degraded substrates. To accomplish this, two
known substrates of IDE were used, insulin and Ab.A b does not
contain a disulfide bond, thus this compound would not be
expected to exhibit alterations in solubility as a result of the
reducing capacity of GSH. In addition, we heat inactivated the
enzyme at the end of the incubation, and added 10
23 M GSH for
a further 15 minutes. Any effect of GSH on substrate solubility at
this point would be due to a direct effect on the hormone, and not
on IDE activity.
As shown above, GSH appears to increase insulin degradation,
while GSSG inhibits it (Figure 9A, left). However, Ab degradation
was unaffected by GSH, while GSSG inhibited (Figure 9B, left),
suggesting that GSSG acts on IDE, while GSH only affects the
disulfide-containing insulin molecule. When IDE is heat-inacti-
vated at the end of the incubation, and additional GSH added,
insulin solubility increases to the level of degradation seen when
GSH is included at the start (Figure 9A, right). The addition of
GSH to Ab after IDE inactivation had little effect (Figure 9B,
right). In the absence of enzyme, GSH did not significantly
increase insulin solubility (data not shown). Thus, GSH is not
acting on IDE itself to increase insulin degradation, but instead, is
reducing the disulfide bonds of partially-degraded insulin. The
insulin disulfide bond reduction effectively increases the TCA
solubility of the substrate, but only after partial degradation of
insulin has occurred.
In order to confirm that GSH was reducing the disulfide bonds
of partially-degraded insulin, we examined the insulin-degrada-
tion products by HPLC analysis. Figure 10A shows a represen-
tative elution profile of
125I-insulin and fragments after incuba-
tion with partially-purified IDE. Figure 10B shows the insulin
elution profile of IDE treated with GSH [10
22 M]. GSH
treatment resulted in a dramatic increase in the formation of a
prominent early insulin product peak (Figure 10A and 10B, peak
1). Previous studies have identified this prominent early peak to
contain partially-degraded, trichloroacetic acid soluble, A-chain
fragments [26]. There was also a substantial decrease in the
production of two later-eluting product peaks (Figure 10A and
10B, peaks 2 and 3). This shift in products is likely to result from
the breaking of a disulfide bond, generating smaller less
hydrophobic peptides. Treatment of the partially-purified en-
zyme with 10 mM GSSG significantly inhibited insulin degrada-
tion (Figure 10C).
Discussion
IDE has been linked to T2DM and AD, thus control of its
function is of interest regarding the etiology of these diseases.
A number of compounds have been reported to alter IDE
activity, including fatty acids, ATP, hydrogen peroxide, and
NO [11,12,34,35,36]. Given the thiol sensitivity of IDE, hydrogen
peroxide and NO likely react with one or more of the cysteines
previously identified to have an effect on activity, namely C178,
C789, C812, C819, or C966 [10,37]. Unlike alkylating reagents
such as N-ethylmaleimide, the reaction of these compounds with
cysteine residues is reversible. This provides the cell with a
potential mechanism to regulate the activity of IDE, depending on
the redox state of the cell. But the redox control of IDE may be
complex as cysteine C178 has been suggested to provide
protection from inactivation by preventing nitrosylation of C110
[37]. However, this effect was seen in a mutated form of IDE with
limited cysteines, and whether it is physiologically relevant is
uncertain as C110 is not nitrosylated in wild type IDE containing
all 13 cysteines. The results presented here add to that complexity
and are significant for several reasons.
First, our results confirm previous work showing that NO
inhibits insulin degradation, and can alter proteasome activity
[11,12]. The fact that NO inhibited the proteasome only when
Figure 10. HPLC analysis of insulin degradation products.
Insulin degradation products were qualitatively measured after
incubation with (A) partially-purified IDE, (B) partially-purified IDE +
GSH [10
22 M], and (C) partially-purified IDE + GSSG [10
22 M]. The peaks
that changed in size with GSH treatment are identified with arrows (1, 2,
and 3). GSH shifted the product pattern by decreasing peaks 2 and 3,
and increasing peak 1. GSSG inhibits IDE and reduced all products.
doi:10.1371/journal.pone.0018138.g010
Redox Control of IDE
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our previous work [25,27,28,34] that IDE can interact with the
proteasome and alter its activity. This is consistent with the known
activity of insulin to decrease cellular protein degradation, and
suggests IDE may act as an intracellular mediator for insulin
action.
Second, we have shown that oxidized glutathione (GSSG) can
inhibit IDE, by reacting with one or more of its cysteines. Thus,
not only can reactive oxygen species (ROS) such as hydrogen
peroxide inhibit IDE directly [35], but increased levels of cellular
GSSG, which results from increased ROS, can decrease IDE
activity. Although glutathionylation is a reversible form of post-
translational modification, it is chemically very different from
nitrosylation. The formation of either type of modification does
not occur by direct addition of a NO group or GSH to protein
cysteines. It is necessary for the cysteine to be in the appropriately
reduced state. In order for nitrosylation to occur, the protein must
lose one electron per sulphur atom and it must lose two electrons for
glutathionylation, which means that less reducing power is
required for the reversal of cysteine nitrosylation [38]. Thus,
how IDE is modified will determine how readily the inhibition
can be reversed.
Third, while GSSG inhibits IDE, reduced glutathione (GSH)
appears to increase insulin degradation. This was not due to an
effect on IDE, but rather on the ability of GSH to reduce the
disulfides in partially degraded insulin as confirmed by HPLC
analysis of the products (Figure 10). Intact insulin is not affected
by GSH. Thus, the redox state of the cell can affect the rate at
which insulin is degraded to small peptides. The effects of both
compounds are seen in the mM range, consistent with the typical
cellular concentration of glutathione. Normally the ratio of GSH
to GSSG is around 10, which would strongly favor insulin
breakdown. However, because GSH and GSSG have reciprocal
action in the same concentration range (Fig. 7), a shift toward
the oxidized state would act to slow insulin degradation; i.e. less
GSH to break the disulfide and more GSSG to inhibit IDE. The
effect of a more oxidizing environment (including increased
GSSG concentrations) would be more evident on lowering Ab
degrading activity, as GSH has no effect to increase its
degradation (Figure 9). These data, along with the previous
studies on ROS and RNS, suggest IDE activity is subject to fine
control by ambient conditions of the cell. Indeed, our results
treating the partially purified enzyme with DTT (Figure 8) and
the low level of endogenous glutathionylation (Figure 5) suggest
that IDE is already partly inhibited upon isolation, although it
cannot be ruled out that this is an artifact of the purification
procedure.
Finally, the effect of GSH is also of interest in historical terms.
In the late 1970’s and early 1980’s there was some debate
whether IDE or glutathione insulin transhydrogenase (GIT, now
identified as protein disulfide isomerase, PDI) acted first on
insulin [39]. The current consensus is that IDE acts first, and our
results indicate that PDI is not required for the action of GSH,
after initial cleavage by IDE. The non-enzymatic action of GSH
may explain why early studies suggested a role for PDI, when the
susceptibility of minimally degraded insulin was unknown. This
action of GSH may also explain why the insulin cleavage
products that accumulate in cells are different than those
generated by IDE in vitro or extracellularly [40,41]. The HPLC
pattern of extracellular
125I-iodoinsulin degradation products is
the same as that generated by purified preparations IDE, with
numerous peaks evident. However, insulin-sized intracellular
products are more limited in number, presumably due to their
rapid breakdown by GSH.
In conclusion the results presented here indicate that insulin
degradation by IDE can be regulated in both positive and
negative ways. We have shown for the first time that IDE can be
glutathionylated by oxidized glutathione. Both nitrosylated and
glutathionylated, forms of IDE are inhibited with respect to
insulin degradation. These modifications are reversible, but
require less reducing power for nitrosylation than for glutathio-
nylation. Insulin degradation can also be accelerated by direct
interaction of GSH with insulin, but only after partial cleavage by
IDE, which presumably allows for distortion of the insulin
molecule and exposure of the disulfide bonds. These findings
suggest that cellular conditions that contribute to NO availability
or a more oxidizing environment may decrease the degradation
of insulin or amyloid b and contribute to the etiology of T2DM
or Alzheimer’s disease, respectively.
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